Wide Ranks

BEAM

Beam Therapeutics Inc.

27.20

Top Statistics
Market Cap 2 B Forward PE -5.72 Revenue Growth -17.00 %
Current Ratio 5.69 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -41.07 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -8.71 Enterprise / Revenue 4.01 Price To Sales Trailing12 Months 6.44
Profitability
Profit Margins -41.07 % Operating Margins -746.40 %
Balance Sheet
Total Cash 925 M Total Cash Per Share 11.63 Total Debt 162 M
Total Debt To Equity 20.48 Current Ratio 5.69 Book Value Per Share 9.97
All Measures
Short Ratio 935.00 % Message Board Id finmb_564610577 Shares Short Prior Month 11 M
Return On Equity -0.1829 City Cambridge Uuid 59de9e0e-05e5-3c20-a484-b2350c3fa77a
Previous Close 25.84 First Trade Date Epoch Utc 1 B Book Value 9.97
Beta 1.86 Total Debt 162 M Volume 631990
Price To Book 2.73 Fifty Two Week Low 20.84 Total Cash Per Share 11.63
Total Revenue 349 M Shares Short Previous Month Date 1 B Target Median Price 48.00
Max Age 86400 Recommendation Mean 2.06 Sand P52 Week Change 0.3133
Operating Margins -746.40 % Target Mean Price 49.20 Net Income To Common -143591008
Short Percent Of Float 0.1890 Implied Shares Outstanding 82 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 925 M Next Fiscal Year End 1 B Revenue Per Share 4.27
Held Percent Insiders 0.0141 Ebitda Margins -46.00 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 25.84
Target Low Price 23.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 24.57
Open 26.09 Free Cashflow -38545624 State MA
Dividend Yield 0.00 % Return On Assets -0.0927 Time Zone Short Name EST
Trailing Eps -1.58 Day Low 26.09 Address1 238 Main Street
Shares Outstanding 82 M Price Hint 2 Target High Price 80.00
Website https://beamtx.com 52 Week Change -0.0313 Average Volume 976262
Forward Eps -4.77 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 556.90 % Is_sp_500 False Regular Market Day High 27.30
Profit Margins -41.07 % Debt To Equity 20.48 Fifty Two Week High 49.50
Day High 27.30 Shares Short 11 M Regular Market Open 26.09
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 4.01
Revenue Growth -17.00 % Shares Percent Shares Out 0.1445 Operating Cashflow -135808000
Currency USD Time Zone Full Name America/New_York Market Cap 2 B
Is_nasdaq_100 False Zip 02142-1016 Quote Type EQUITY
Industry Biotechnology Long Name Beam Therapeutics Inc. Regular Market Day Low 26.09
Held Percent Institutions 0.9311 Current Price 27.20 Address2 9th Floor
Enterprise To Ebitda -8.71 Financial Currency USD Current Ratio 5.69
Gross Margins -16.17 % Industry Disp Biotechnology Number Of Analyst Opinions 15
Country United States Float Shares 64 M Two Hundred Day Average 26.68
Enterprise Value 1 B Price To Sales Trailing12 Months 6.44 Forward PE -5.72
Regular Market Volume 631990 Ebitda -160828992 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.

Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.